Tyler Seibert, Radiation Oncologist and Cancer Scientist at UC San Diego, shared on X:
“Daniel Krauss: RTOG-0815 long-term results
- stADT improves PFS, MFS – but not OS
- no clear subgroup that did not benefit (maybe need to look at biomarkers? )
- stADT not worse for non-PC death.”
This might be interesting:
15 Posts Not To Miss From ASCO GU 2026
